US pharmacy chain Rite Aid closes final stores https://t.co/iPMCe6W6yY ...

Rite Aid, a once-national pharmacy chain popular for its in-store ice cream scoops, has closed its doors. The company announced all its stores have "now closed" in a statement posted to its website. “We thank our loyal customers for their many years of support,” the statement reads. Rite Aid announced it filed for Chapter 11 bankruptcy in May, the second time since October 2023. As part of its bankruptcy plan, the chain announced it would be closing all of its stores. Rite Aid CEO Matt Schroeder said in ...

Phase 1 study to progress to the next dose level of 75mCi in patients with HER2+ advanced solid tumors, instead of the protocol-planned dose of 40mCiSYDNEY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has received a positive recommendation from the Data Safety and Monitori ...

Financial Data and Key Metrics Changes - The company reported an underlying EBITDA of $20 million for FY '25, with operating cash flow also at $20 million and reduced debt levels to $67.7 million [23][34] - The total FY '25 dividend was $1.45 per share, representing a gross fully imputed dividend of $2.01 per share, which is 47% of AFFO, aligning with the target payout ratio of 40% to 70% [21][34] Business Line Data and Key Metrics Changes - Radius Care operates 24 aged care homes and four retirement villages, focusing on high acuity aged residential care and health services [12][13] - The company acquired the 109-bed St. Elisa care home in Christchurch for just under $1.1 million, expected to contribute to earnings from the second half of FY '26 [14][15] - CBIZ Catering Limited, acquired in October 2024, contributed $4.1 million in revenue and $500,000 in EBITDA for the period from October 2024 to March 2025 [15][16] Market Data and Key Metrics Changes - Occupancy rates are currently over 95%, with the latest figure at 95.8% [13][32] - The company has expanded into in-home care services, addressing the needs of New Zealand's aging population [17] Company Strategy and Development Direction - The company is in growth mode, focusing on capital light acquisitions, revenue diversification, and extending home opportunities [14][20] - The updated capital management framework aims to support reinvestment in core operating assets while maintaining sustainable dividend growth [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for growth across key financial metrics in FY '26, including underlying EBITDA and AFFO [21][35] - The company anticipates strong trading performance, with an upgraded guidance for underlying EBITDA in the first half of FY '26 to be between $14 million and $16 million [33] Other Important Information - The company has a strong focus on staff training and well-being, with a Net Promoter Score of 74 for facility managers, indicating high employee engagement [26][28] - The company has developed RadPro, an operational template that supports resident-centric decision-making and continuous improvement [18][39] Q&A Session Summary Question: Can you provide more details on RadPro and its development? - RadPro is the operating system developed over 21 years, encompassing all aspects of operations, including staff education and efficiency tools. It is now being expanded into home care services and has potential for marketing outside New Zealand [38][40]

Financial Performance & Growth - The company reported a 39% profit growth [30] - Underlying EBITDA for 1H26 is projected to be $14 million to $16 million [30, 56] - Underlying EBITDA increased by 20% to $23.5 million from $19.5 million [43] - Underlying EBITDAR Per Care Bed increased by 13% to $27.9K from $24.7K [45] - Total FY25 cash dividend was 1.45cps, compared to 0.70cps in FY24 [45] Expansion & Acquisitions - Acquired St Allisa, a 109-bed care home, through a leaseback arrangement [24, 27, 30] - Acquired 51% of Cibus Catering Limited, resulting in a $4.1 million revenue uplift [30] - Pursuing capital-light expansion focused on new-build 100-bed care homes leased from private investors [28] Operational Efficiency & Staffing - Company-wide staff turnover decreased by 30% year-on-year, reaching a record low [48] - 86% of care homes audited in FY25 received 4-Year Certification [49] - Average occupancy is trending upwards, reaching approximately 95% [50] - The company acquired 920,000 shares for $280,000, with an average buyback price of 30.4cps [39, 40]

Core Insights - Radiopharm Theranostics is advancing its clinical pipeline with significant milestones, including FDA Fast Track Designation for RAD101 and clearance for higher dosing of RAD204 [3][5][6] - The company confirmed a cash runway extending through mid-2026, with a year-end cash balance of $29.12 million, up from $18.58 million the previous year [10][12] Program and Business Updates - RAD204, a nanobody targeting PD-L1, is on track for higher dosing at 60mCi of Lu177, with enrollment for the second cohort expected to complete soon [6] - RAD202, targeting HER2, has initiated its Phase 1 HEAT trial, with preliminary data anticipated by the end of 2025 [6] - The company has established supply agreements for key radioisotopes, enhancing its clinical trial capabilities [3][12] Financial Update - For the fiscal year ending June 30, 2025, net cash outflows from operating activities totaled $36.67 million, primarily due to research and development expenditures [10][12] - The company received $4.58 million for research and development tax incentives for the 2024 financial year [12]

Lu177-B7H3 monoclonal antibody is first in class targeted radiopharmaceutical in development against the 4lg subtype of B7-H3 On track to initiate first-in-human study of RV-01 in solid tumors in 4Q25 "The high affinity and selectivity of RV-01 for the 4Ig isoform of B7H3 allows the antibody to bypass the soluble 2Ig isoform in the blood, boost binding of the radiopharmaceutical to tumor targets and avoid the formation of immune complexes in circulation," noted David Piwnica-Worms, M.D., Ph.D., Professor, M ...

Core Viewpoint - Rite Aid is closing an additional 114 stores as part of its second bankruptcy proceedings in less than two years, driven by mounting debt, sluggish sales, and competition in the pharmacy industry [1][3][4]. Group 1: Bankruptcy and Store Closures - Rite Aid filed for Chapter 11 bankruptcy protection in May 2023, just eight months after exiting its first bankruptcy [2][4]. - The bankruptcy court in New Jersey approved the closure of 114 stores, with the majority located in Pennsylvania [1][2][7]. - The company has already closed 154 stores as part of its store optimization plan, reducing its footprint to approximately 1,245 locations [3][4]. Group 2: Financial Challenges - Rite Aid emerged from its first bankruptcy with $2.5 billion in liabilities, indicating ongoing financial struggles [4]. - The company has faced increased competition from other pharmacy chains such as Walgreens, CVS, Walmart, and Amazon, which has contributed to its financial difficulties [4][6]. Group 3: Industry Context - Industry experts anticipate further closures across the pharmacy sector as companies adjust to market demands and rightsize their operations [6]. - The rapid expansion of pharmacy locations has outpaced the actual need for pharmacies, leading to financial strain on companies like Rite Aid [6].

SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company's Scientific Advisory Board (SAB). DrSartor has also held senior roles at LSU Health Sciences Center, Dana‑Farber/Harvard Medical School, and as Medical Oncology Co‑Chair of the GU C ...

Core Insights - Radiopharm Theranostics has completed the preclinical data package for RAD 402, an anti-Kallikrein Related Peptidase 3 (KLK3) monoclonal antibody radiotherapeutic, and is preparing to initiate a Phase 1 clinical trial for prostate cancer in the second half of 2025 [1][2][3] Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs, listed on ASX (RAD) and NASDAQ (RADX) [5] - The company has a diverse pipeline that includes one Phase 2 and three Phase 1 trials targeting various solid tumors, including lung, breast, and brain cancers [5] Partnership and Development - A supply agreement has been signed with Cyclotek to radiolabel RAD 402 with Terbium-161 (Tb), which is crucial for the upcoming Phase 1 clinical trial [1][3] - Cyclotek, a leading radiopharmaceutical manufacturer in Australia and New Zealand, will produce and provide doses of Tb-labeled RAD 402 [6][4] Therapeutic Focus - RAD 402 is designed to target KLK3, which is highly expressed in prostate tissue, potentially leading to improved therapeutic efficacy due to the unique properties of Tb compared to other radionuclides [2][4] - The partnership aims to enhance patient outcomes by improving the accessibility of radiopharmaceuticals [7][8]